HOME >> MEDICINE >> NEWS
Narcotic drugs effective for severe, chronic pain in older patients

Narcotic medications can safely and effectively ease severe, chronic pain in older people with little risk that these patients will seek ever-increasing doses, UCSF medical scientists have found. Younger patients, however, are likely to want to rapidly increase their medication dose, the researchers found, posing serious potential health consequences.

The study is the first to systematically compare younger versus older patients' desires/needs to escalate the dose of opioid pain medications they take -- a class of drugs including morphine, methadone and oxycodone (sold as OxyContin, Percocet among others). Based on the new findings, the researchers suggest that the drugs may be under-prescribed for older patients, yet pose unique risks for younger patients.

Opioids have long been used for unremitting pain caused by nerve damage, arthritis and other diseases, but clinicians and patients often worry that use of the drugs will lead to patient requests for ever-increasing doses. Extended opioid use at high doses can alter immune and hormonal function and, ironically, increase pain sensitivity. The escalating drug need, stemming from "tolerance" to a given dose, also can become very costly.

The new findings show that patients 60 or older faced a much lower risk of opioid "dose escalation" than did younger patients. Older patients also received long-term pain relief from the opioids whereas younger patients showed no long-term benefit.

The discovery about opioid tolerance and age was uncovered from a study of patient records, and confirmed in animal studies. The findings are being published in two papers in the June issue of Anesthesia and Analgesia.

"We have found that older patients, often discouraged from using opioids for pain management, actually gain significant long-term relief with minimal risk of excessive dose escalation or toxicity," said Pamela Palmer, MD, PhD, professor of anesthesia at UCSF and senior author of the t
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
20-May-2005


Page: 1 2 3 4

Related medicine news :

1. UIC researchers to develop new drugs to fight bioterrorism
2. Statin drugs may delay progressive artery damage in children
3. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
4. Experts call for urgent research into anti-epileptic drugs given to children
5. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
6. Antipsychotic drugs increase risk of death in older people with dementia
7. Antipsychotic drugs increase risk of death in older people with dementia
8. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
9. Panel offers guidelines on skin reactions to new class of cancer drugs
10. Blood-thinning drugs need closer monitoring
11. Comparison of patients access to new and better cancer drugs reveals inequalities between countries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Narcotic drugs effective for severe chronic pain older patients

(Date:5/23/2013)... important human pathogen that can cause rapidly progressing, life ... said., "Until now we have not known how it ... long-standing mystery how it attaches to the airway to ... not get any symptoms, while some people progress to ... know the detail of how the bacterium colonises the ...
(Date:5/23/2013)... WEDNESDAY, May 22 (HealthDay News) -- The success of an ... with a serious airway malformation sheds light on new technology ... report in the May 23 New England Journal of ... At first, the baby born five weeks early seemed perfectly ... when he was 6 weeks old. Just two weeks later, ...
(Date:5/23/2013)... DRE, Inc. is now offering the ... solution to upgrade older model DRE or BFW halogen ... system. , DRE and BFW customers can easily ... halogen headlights to LED with DRE’s American-made Xavier-C3 LED ... Kit provides a bright, clean and even field of ...
(Date:5/23/2013)... 2013 In Florida, residents have not been ... mean, however, that Florida’s good luck will continue, warns Rick ... year, he encourages residents, it is important to prepare as ... are predicting there to be a 50-percent chance that a ... hurricane season lasting from June 1 to November 30 in ...
(Date:5/23/2013)... Natchitoches, LA (PRWEB) May 23, 2013 The ... website, has showed that Louisiana still tops the rest of ... annual average of $2,699 is more than double of that ... factors determine auto insurance rates, and those factors vary from ... that may be causing these high rates. , Compared ...
Breaking Medicine News(10 mins):Health News:New discovery in fight against deadly meningococcal disease 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 2Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2Health News:Cunningham Financial Group Wants Motorists to Understand Their Rates as Louisiana’s Auto Insurance Rates Remain the Highest in the Nation 2
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, ... announced today that it will present new results ... an industry conference sponsored by the PML Consortium ... Idec).  JC polyomavirus (JCV) is the causative agent ... tyrosine kinase inhibitor in an extended release formulation, ...
(Date:5/23/2013)... 2013 InspireMD, Inc. ("InspireMD" ... in embolic protection stents, today announced new 6-month ... Elevation Reperfusion) trial demonstrating that the MGuard Embolic ... eluting stents in all-cause mortality in ST segment ... trial were presented at the InspireMD STEMI Symposium ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
Cached News: